Chemomab Therapeutics (CMMB) Tops Q3 EPS by 4c

Chemomab Therapeutics (NASDAQ: CMMB) reported Q3 EPS of $0.02, $0.04 better than the analyst estimate of ($0.02).

For earnings history and earnings-related data on Chemomab Therapeutics (CMMB) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• DeFi Technologies (DEFT) PT Lowered to $1 at Benchmark Following Q2 Miss
• The free USDA tool that tracks egg prices at $0.62/dozen before your data vendor does